Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
23.32
+0.28 (1.22%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Structure Therapeutics Employees
Structure Therapeutics had 163 employees as of December 31, 2024. The number of employees increased by 70 or 75.27% compared to the previous year.
Employees
163
Change (1Y)
70
Growth (1Y)
75.27%
Revenue / Employee
n/a
Profits / Employee
-$751,693
Market Cap
1.34B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Dec 31, 2022 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
GPCR News
- 9 days ago - What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
- 27 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 4 weeks ago - Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate - Seeking Alpha
- 2 months ago - Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 3 months ago - Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst - Benzinga
- 4 months ago - Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - GlobeNewsWire
- 5 months ago - Structure Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 5 months ago - Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity - GlobeNewsWire